Previous 10 | Next 10 |
The FDA accepts DiaMedica Therapeutics' (NASDAQ: DMAC ) Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). More news on: DiaMedica Therapeutics Inc., Healthcare stocks news, Read more ...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). The Phase II trial is designed to assess the safety and efficacy of...
Gainers: Akcea Therapeutics (NASDAQ: AKCA ) +29% . Liquid Media Group (NASDAQ: YVR ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +20% . Sutro Biopharma (NASDAQ: STRO ) +19% . Livongo Health (NASDAQ: LVGO ) +15% . Motus GI Holdings (NASDAQ: MOTS ) +12% . Teekay Tankers (NYSE: TNK )...
The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with this Read more ...
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3 rd Annual Best Ideas Growth (BIG3) Conference on Thursday, September 12th, 2019, at the Parker New York in New York City....
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis, Minnesota. Rick Pauls, President and CEO of DiaMedica Therapeutics wil...
DiaMedica Therapeutics Inc. (DMAC) Q2 2019 Earnings Conference Call August 14, 2019 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Tho...
DiaMedica Therapeutics (NASDAQ: DMAC ): Q2 GAAP EPS of -$0.21 beats by $0.05 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Phase Ib study of DM199 in Chronic Kidney Disease enrollment complete Encouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II CKD protocol submitted, trial initiation expected H2 2019 with interim analysis Q...
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on Tuesday, August 13 th . DiaMedica will host a live conference call on Wednesday, August 14 th ...
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. Website:
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel trea...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its previously announced $11.8 million private placement to accredited investors. The Company sold approximatel...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...